Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Summit Therapeu ADR (SMMT)

Summit Therapeu ADR (SMMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,173,736
  • Shares Outstanding, K 771,150
  • Annual Sales, $ 0 K
  • Annual Income, $ -221,320 K
  • EBIT $ -935 M
  • EBITDA $ -935 M
  • 60-Month Beta -1.53
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 72.68

Options Overview Details

View History
  • Implied Volatility 0.00% (-92.92%)
  • Historical Volatility 55.29%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 152.33% on 10/13/25
  • IV Low 0.00% on 12/26/25
  • Expected Move (DTE 7) 1.29 (7.03%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 12
  • Volume Avg (30-Day) 2,578
  • Put/Call OI Ratio 0.99
  • Today's Open Interest 93,863
  • Open Int (30-Day) 106,430
  • Expected Range 17.09 to 19.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.27
  • Number of Estimates 3
  • High Estimate -0.17
  • Low Estimate -0.32
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -237.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.76 +8.74%
on 12/02/25
19.10 -4.58%
on 12/05/25
+0.41 (+2.27%)
since 11/26/25
3-Month
15.62 +16.68%
on 11/21/25
25.49 -28.50%
on 10/13/25
-2.73 (-13.01%)
since 09/26/25
52-Week
15.55 +17.20%
on 04/07/25
36.91 -50.62%
on 04/24/25
-1.06 (-5.47%)
since 12/26/24

Most Recent Stories

More News
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 67,483 shares of common stock....

SMMT : 18.13 (-1.36%)
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

The First Phase III Study Testing Ivonescimab Now Represents the First Statistically Significant OS Benefit Achieved by an Ivonescimab-Containing Regimen Ivonescimab Plus...

SMMT : 18.13 (-1.36%)
Summit Therapeutics to Present at Upcoming Investor Conferences

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at four upcoming investor conferences during the remainder...

SMMT : 18.13 (-1.36%)
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Conducted by Akeso, HARMONi-A Represents the First Statistically Significant OS Benefit Achieved in a Phase III Study by an Ivonescimab-Containing Regimen

SMMT : 18.13 (-1.36%)
Why Wall Street Is Backing These 3 Comeback Stocks

It's not too late to get in on these potential comeback winners, although investors need to be willing to accept some risk.

TTD : 37.99 (-0.34%)
SMMT : 18.13 (-1.36%)
SFM : 79.99 (+0.39%)
AMZN : 232.37 (unch)
WMT : 111.66 (+0.04%)
Summit Therapeutics Raises $500 Million in Private Placement

Fundraise Led by Leading Biopharma Institutional Investors & Insiders $500 Million in Gross & Net Proceeds Raised at Yesterday’s Closing Price of $18.74

SMMT : 18.13 (-1.36%)
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

Summit Plans to Submit a BLA in Q4 2025 for Ivonescimab Based on HARMONi Global Phase III Study Results Expansion of Summit’s Global Phase III Development Program Starts...

SMMT : 18.13 (-1.36%)
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Clinically Meaningful Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial...

SMMT : 18.13 (-1.36%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are...

SMMT : 18.13 (-1.36%)
Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

HARMONi-GI3 is the Fourth Global Phase III Study of Ivonescimab and First Global Study beyond NSCLC Clinical Trial Site Activations Planned to Begin This Quarter in the...

SMMT : 18.13 (-1.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 19.21
2nd Resistance Point 18.87
1st Resistance Point 18.63
Last Price 18.13
1st Support Level 18.04
2nd Support Level 17.69
3rd Support Level 17.45

See More

52-Week High 36.91
Fibonacci 61.8% 28.75
Fibonacci 50% 26.23
Fibonacci 38.2% 23.71
Last Price 18.13
52-Week Low 15.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar